as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,860.0
Change
+5.9 (0.32%)
Open
₹1,857.6
Prev. Close
₹1,854.1
Day High
₹1,890.5
Day Low
₹1,845.1
Volume Analysis
Traded
257,674
Delivered
176,977
Delivery %
68.68%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (23.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (3)
- •Strong 3-year EPS growth (34.3%)
- •Strong 3-year revenue growth (15.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,930.7 | ₹1,910.6 | ₹1,885.3 | ₹1,865.2 | ₹1,839.9 | ₹1,819.8 | ₹1,794.5 |
| Fibonacci | ₹1,910.6 | ₹1,893.26 | ₹1,882.54 | ₹1,865.2 | ₹1,847.86 | ₹1,837.14 | ₹1,819.8 |
| Camarilla | ₹1,872.49 | ₹1,868.32 | ₹1,864.16 | ₹1,865.2 | ₹1,855.84 | ₹1,851.68 | ₹1,847.52 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+33.03%
1 Week
-2.09%
1 Month
-3.07%
3 Months
-2.68%
6 Months
+16.1%
1 Year
+29.33%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹588.32
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
15.61%
Net margin 14.16% × asset turnover 0.73x × equity multiplier 1.51x
Company Overview
Sector
Healthcare
Market Cap
₹46,508 Cr
P/E (TTM)
32.3
ROE
15.7%
Book Value
₹342.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Ipca Laboratories Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Valuation (34/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (23.0%); promoter holding is falling. Strong 3-year EPS growth (34.3%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- −Stock is trading at 5.36 times its book value
- −Company has a low return on equity of 12.9% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Ipca Labs held Q2 FY27 earnings call; consolidated revenue rose 14% to INR2,910 crore, EBITDA margin 22.97%.
Audio link shared for Q2FY27 earnings and business update conference call held on November 5, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | 2,788 | 2,910 |
| Expenses + | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | 2,119 | 2,236 |
| Operating Profit | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 | 533 | 484 | 670 | 673 |
| OPM % | 18.0% | 16.0% | 16.0% | 19.0% | 19.0% | 21.0% | 19.0% | 18.0% | 21.0% | 22.0% | 20.0% | 24.0% | 23.0% |
| Other Income + | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 | 38 | 48 | 25 | 1 |
| Interest | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 | 18 | 20 | 12 | 13 |
| Depreciation | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 | 108 | 107 | 111 | 115 |
| Profit before tax | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 | 446 | 404 | 572 | 547 |
| Tax % | 39.0% | 23.0% | 96.0% | 31.0% | 29.0% | 25.0% | 49.0% | 29.0% | 28.0% | 18.0% | 24.0% | 26.0% | 28.0% |
| Net Profit + | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 | 389 |
| EPS in Rs | 6 | 7 | 2 | 8 | 9 | 10 | 3 | 9 | 11 | 13 | 12 | 16 | 15 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 27 | 33 | 34 | 32 | 16 | 9 | 11 | 10 | 9 | 7 | 6 | 21 | 14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,599 | 10,479 |
| Expenses + | 2,604 | 2,573 | 2,705 | 2,803 | 3,051 | 3,715 | 3,843 | 4,472 | 5,272 | 6,338 | 7,166 | 7,609 | 8,119 |
| Operating Profit | 541 | 294 | 451 | 455 | 695 | 904 | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,990 | 2,360 |
| OPM % | 17.0% | 10.0% | 14.0% | 14.0% | 19.0% | 20.0% | 29.0% | 23.0% | 15.0% | 17.0% | 19.0% | 21.0% | 23.0% |
| Other Income + | 32 | 21 | 11 | 41 | 56 | 65 | 59 | 54 | 123 | 17 | -114 | 80 | 112 |
| Interest | 32 | 35 | 27 | 28 | 22 | 20 | 12 | 11 | 48 | 141 | 88 | 79 | 62 |
| Depreciation | 180 | 163 | 173 | 178 | 182 | 210 | 209 | 232 | 262 | 357 | 398 | 418 | 440 |
| Profit before tax | 361 | 117 | 262 | 291 | 546 | 739 | 1,389 | 1,136 | 745 | 843 | 1,131 | 1,573 | 1,970 |
| Tax % | 28.0% | 18.0% | 26.0% | 18.0% | 19.0% | 18.0% | 17.0% | 20.0% | 34.0% | 37.0% | 30.0% | 24.0% | — |
| Net Profit + | 254 | 93 | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 1,184 | 1,484 |
| EPS in Rs | 10 | 4 | 8 | 9 | 18 | 24 | 45 | 35 | 19 | 22 | 29 | 45 | 55 |
| Dividend Payout % | 5.0% | 0.0% | 6.0% | 5.0% | 9.0% | 10.0% | 9.0% | 11.0% | 22.0% | 19.0% | 14.0% | 0.0% | — |
| Sales growth | -4 | -9 | 10 | 3 | 15 | 23 | 17 | 7 | 7 | 24 | 16 | 8 | 12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,602 | 4,676 | 5,467 | 5,817 | 6,307 | 6,923 | 8,038 | 8,653 |
| Borrowings + | 935 | 867 | 716 | 628 | 465 | 501 | 265 | 807 | 1,481 | 1,438 | 1,363 | 809 | 753 |
| Other Liabilities + | 669 | 765 | 788 | 799 | 961 | 1,130 | 1,099 | 1,338 | 1,300 | 3,326 | 3,432 | 3,477 | 3,702 |
| Total Liabilities | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,623 | 11,097 | 11,744 | 12,350 | 13,133 |
| Fixed Assets + | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,418 | 2,751 | 4,554 | 4,267 | 4,627 | 4,740 |
| CWIP | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 | 622 | 773 | 832 |
| Investments | 16 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 | 980 | 844 | 1,055 |
| Other Assets + | 1,729 | 1,723 | 1,746 | 2,003 | 2,422 | 2,756 | 3,254 | 3,924 | 5,105 | 5,339 | 5,875 | 6,106 | 6,507 |
| Total Assets | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,637 | 8,623 | 11,097 | 11,744 | 12,350 | 13,133 |
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | 945 | 1,321 | 1,142 |
| Cash from Investing Activity + | -689 | -218 | -149 | -135 | -165 | -509 | -521 | -851 | -725 | -1,215 | -870 | -247 |
| Cash from Financing Activity + | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | -553 | -283 | -754 |
| Net Cash Flow | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 432 | 588 | -823 | 169 | 142 |
| Free Cash Flow | -207 | 463 | 147 | 206 | 322 | 277 | 731 | 380 | 347 | 543 | 551 | 486 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 100 | 251 | 74 | 88 | 88 | 80 | 86 | 80 | 110 | 94 | 97 | 78 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 8.93% | 8.82% | 9.07% | 8.64% | 8.53% | 8.45% | 8.41% | 8.09% | 7.33% | 7.21% | 7.19% | 7.15% |
| Promoters | 46.29% | 46.3% | 46.3% | 46.3% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
| Government | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.0% |
| FII | 10.27% | 10.51% | 10.85% | 10.83% | 11.06% | 10.75% | 10.67% | 10.42% | 10.62% | 10.63% | 10.72% | 11.53% |
| DII | 34.19% | 34.05% | 33.46% | 33.9% | 35.36% | 35.73% | 35.88% | 36.45% | 36.99% | 37.13% | 37.04% | 36.6% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Ipca Laboratories Ltd (this stock) | 46,508 | 32.3 | 5.36 | 15.7% |
| Glaxosmithkline Pharma Lt | 45,576 | 40.2 | 24.22 | 45.6% |
| Emcure Pharmaceuticals L | 44,370 | 39.9 | 8.29 | 20.1% |
| Anthem Biosciences Ltd | 51,355 | 81.4 | 15.65 | 22.3% |
| Ajanta Pharma Limited | 41,393 | 32.8 | 8.51 | 27.1% |
| Sai Life Sciences Limited | 41,003 | 107.0 | 15.19 | 15.4% |
| Gland Pharma Limited | 53,710 | 42.9 | 5.01 | 10.7% |
Which Mutual Funds Hold Ipca Laboratories Ltd?
Frequently Asked Questions about Ipca Laboratories Ltd
Ipca Laboratories Ltd (IPCALAB) closed at ₹1,860.0 on NSE on 19 November 2026, up 5.9 (0.32%) from the previous close.
Ipca Laboratories Ltd trades on the NSE (National Stock Exchange of India) under the symbol IPCALAB.
Ipca Laboratories Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 32.3.
Ipca Laboratories Ltd has a dividend yield of 0.33%.
Ipca Laboratories Ltd's 52-week high is ₹2,039.0 and its 52-week low is ₹1,362.0.
Ipca Laboratories Ltd has a market capitalisation of ₹46,508 crore.
Ipca Laboratories Ltd has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Ipca Laboratories Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.